Global Autoimmune Partnering 2010-2017: Deal trends, players and financials

Description: Global Autoimmune Partnering 2010 to 2017 provides the full collection of Autoimmune disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Autoimmune partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Autoimmune partnering agreement structure
Autoimmune partnering contract documents
Top Autoimmune deals by value
Most active Autoimmune dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Autoimmune disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Autoimmune deals.

The report includes coverage of the following autoimmune diseases:

Multiple sclerosis, Restless leg syndrome, Eczema, Alopecia, Psoriasis, Celiac disease, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Glomerulonephritis, Endometriosis, Immune thrombocytopenic purpura, Neutropenia, Graft versus host disease, Scleroderma, Systemic lupus erythematosus, Addison's disease, Diabetes Type 1, Ankylosing spondylitis, Juvenile arthritis, Psoriatic arthritis, Rheumatoid arthritis, Sarcoidosis, Meniere's disease, and other autoimmune disorders.

The report presents financial deal terms values for Autoimmune deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Autoimmune dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Autoimmune dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Autoimmune deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Autoimmune dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Autoimmune deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Autoimmune partnering deals by specific Autoimmune target announced since 2010. The chapter is organized by specific Autoimmune therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Autoimmune partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Autoimmune partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Autoimmune technologies and products.

Contents:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Autoimmune dealmaking
  2.1. Introduction
  2.2. Autoimmune partnering over the years
  2.3. Autoimmune partnering by deal type
  2.4. Autoimmune partnering by industry sector
  2.5. Autoimmune partnering by stage of development
  2.6. Autoimmune partnering by technology type
  2.7. Autoimmune partnering by therapeutic indication

Chapter 3 - Financial deal terms for Autoimmune partnering
  3.1. Introduction
  3.2. Disclosed financials terms for Autoimmune partnering
  3.3. Autoimmune partnering headline values
  3.4. Autoimmune deal upfront payments
  3.5. Autoimmune deal milestone payments
  3.6. Autoimmune royalty rates

Chapter 4 - Leading Autoimmune deals and dealmakers
  4.1. Introduction
  4.2. Most active in Autoimmune partnering
  4.3. List of most active dealmakers in Autoimmune
  4.4. Top Autoimmune deals by value

Chapter 5 - Autoimmune contract document directory
  5.1. Introduction
  5.2. Autoimmune partnering deals where contract document available

Chapter 6 - Autoimmune dealmaking by therapeutic target
  6.1. Introduction
  6.2. Deals by Autoimmune therapeutic target

Appendices

Appendix 1 - Directory of Autoimmune deals by company A-Z 2010 to 2017
Appendix 2 - Directory of Autoimmune deals by deal type 2010 to 2017
Appendix 3 - Directory of Autoimmune deals by stage of development 2010 to 2017
Appendix 4 - Directory of Autoimmune deals by technology type 2010 to 2017

Further reading on dealmaking
Deal type definitions

About the Publisher
Table of figures:

Figure 1: Autoimmune partnering since 2010
Figure 2: Autoimmune partnering by deal type since 2010
Figure 3: Autoimmune partnering by industry sector since 2010
Figure 4: Autoimmune partnering by stage of development since 2010
Figure 5: Autoimmune partnering by technology type since 2010
Figure 6: Autoimmune partnering by indication since 2010
Figure 7: Autoimmune deals with a headline value
Figure 8: Autoimmune deals with upfront payment values
Figure 9: Autoimmune deals with milestone payment
Figure 10: Autoimmune deals with royalty rates
Figure 11: Active Autoimmune dealmaking activity- 2010 to 2017
Figure 12: Top Autoimmune deals by value since 2010


Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name:   Global Autoimmune Partnering 2010-2017: Deal trends, players and financials
Web Address:    http://www.researchandmarkets.com/reports/3162394/
Office Code:    SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Formats</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>☐</td>
<td>USD 2995</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users:</td>
<td>☐</td>
<td>USD 4495</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>☐</td>
<td>USD 8995</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>☐</td>
<td>USD 14995</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr ☐  Mrs ☐  Dr ☐  Miss ☐  Ms ☐  Prof ☐  Last Name: _______________________
First Name: _______________________
Email Address: * _______________________
Job Title: _______________________
Organisation: _______________________
Address: _______________________
City: _______________________
Postal / Zip Code: _______________________
Country: _______________________
Phone Number: _______________________
Fax Number: _______________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB9533083313083</td>
</tr>
</tbody>
</table>
| Bank Address  | Ulster Bank,
                27-35 Main Street,
                Blackrock,
                Co. Dublin,
                Ireland. |

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp